Literature DB >> 10799661

The effects of bile acids on beta-adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes.

H Gazawi1, P Ljubuncic, U Cogan, E Hochgraff, D Ben-Shachar, A Bomzon.   

Abstract

Bile acids have been proposed as a causative factor for the cardiomyopathy of cholestatic liver disease, since they cause negative inotropism and chronotropism and attenuate cardiac responsiveness to sympathetic stimulation. Bile acids can also modify membrane fluidity and generate reactive oxygen species (ROS). The effects of 10(-6)-10(-3) M deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA) and their taurine conjugates, TDCA and TCDCA, on (1) the binding characteristics of beta-adrenoceptors, (2) membrane fluidity, and (3) the extent of lipid peroxidation in rat cardiac membranes were assessed. The results were compared to the effects of the oxidant, 10(-4)-10(-3) M hydrogen peroxide (H(2)O(2)), and the membrane-fluidizing compound, 5 x 10(-5) M 2-(2-methoxyethoxy)ethyl 8-(cis-2-n-octylcyclopropyl)octanoate (A(2)C). Cardiac beta-adrenoceptor density alone was reduced at 10(-4) M bile acid concentration while, at 10(-3) M bile acids, reductions in both receptor density and affinity were seen. At 10(-4) M H(2)O(2), receptor number and affinity were reduced, whereas A(2)C increased receptor affinity without affecting receptor density. Bile acids (10(-3) M) and 10(-4) M H(2)O(2) reduced membrane fluidity. H(2)O(2) caused a concentration-dependent increase in the extent of lipid peroxidation, whereas the bile acids and A(2)C had no effect. Bile acids (10(-4) M) reduced beta-adrenoceptor density in the absence of variations in membrane fluidity and in the extent of membrane lipid peroxidation. This result suggests that bile acids, at concentrations equivalent to the plasma/serum total or estimated free bile acid concentration, may have a possible role in the etiology of cardiomyopathy of cholestatic liver disease. At 10(-3) M bile acid concentration, beta-adrenoceptor number and affinity were adversely affected, accompanied by a decrease in membrane fluidity but without any significant increase in the extent of membrane lipid peroxidation. Although cardiac beta-adrenoceptor density and affinity and membrane fluidity were adversely affected by bile acids, the relevance of these findings to our understanding of the etiological basis of hepatic cardiomyopathy is questionable, since such concentrations exceeded the highest concentrations seen in the plasma and/or tissues of patients with cholestatic liver disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799661     DOI: 10.1016/s0006-2952(00)00259-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  Cardiomyopathy reverses with recovery of liver injury, cholestasis and cholanemia in mouse model of biliary fibrosis.

Authors:  Moreshwar S Desai; Zeena Eblimit; Sundararajah Thevananther; Astrid Kosters; David D Moore; Daniel J Penny; Saul J Karpen
Journal:  Liver Int       Date:  2014-01-12       Impact factor: 5.828

2.  Cardiac structural and functional alterations in infants and children with biliary atresia, listed for liver transplantation.

Authors:  Moreshwar S Desai; Shabier Zainuer; Curtis Kennedy; Debra Kearney; John Goss; Saul J Karpen
Journal:  Gastroenterology       Date:  2011-07-14       Impact factor: 22.682

3.  Cirrhotic cardiomyopathy.

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2008-11-11       Impact factor: 6.047

4.  On the in vitro vasoactivity of bile acids.

Authors:  P Ljubuncic; O Said; Y Ehrlich; J B Meddings; E A Shaffer; A Bomzon
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

5.  Hypertrophic cardiomyopathy and dysregulation of cardiac energetics in a mouse model of biliary fibrosis.

Authors:  Moreshwar S Desai; Zainuer Shabier; Michael Taylor; Fong Lam; Sundararajah Thevananther; Astrid Kosters; Saul J Karpen
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

6.  Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.

Authors:  J H Henriksen; J P Gøtze; S Fuglsang; E Christensen; F Bendtsen; S Møller
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

7.  Bile acids induce arrhythmias: old metabolite, new tricks.

Authors:  Moreshwar S Desai; Daniel J Penny
Journal:  Heart       Date:  2013-08-22       Impact factor: 5.994

8.  Cirrhotic cardiomyopathy: review of pathophysiology and treatment.

Authors:  Maneerat Chayanupatkul; Suthat Liangpunsakul
Journal:  Hepatol Int       Date:  2014-07       Impact factor: 6.047

Review 9.  Gut microbiome - A potential mediator of pathogenesis in heart failure and its comorbidities: State-of-the-art review.

Authors:  Petra Mamic; Thanat Chaikijurajai; W H Wilson Tang
Journal:  J Mol Cell Cardiol       Date:  2020-12-09       Impact factor: 5.000

10.  In vivo and ex vivo effects of propofol on myocardial performance in rats with obstructive jaundice.

Authors:  Hong-Mei Ren; Li-Qun Yang; Zhi-Qiang Liu; Cai-Yang Chen; Chi-Wai Cheung; Kun-Ming Tao; Jian-Gang Song; Wu-Rong Chen; Wei-Feng Yu
Journal:  BMC Gastroenterol       Date:  2011-12-28       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.